We describe here the exploitation of the therapeutic efficacy of our anti-TERT-based ACT approach in more aggressive haematological cancer settings, such as AML and B-ALL, to validate its versatility as a widespread anti-tumour immunotherapy for leukemic diseases. The gene discussed is TERT; the disease is neoplasm.